Cargando…

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients

The presence of comutations (co-mut+) in DNA damage response and repair (DDR) pathways was associated with improved survival for immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). However, it remains unknown whether co-mut+ status could be a predictive biomarker for imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Anning, Nie, Wei, Zhou, Yan, Li, Changhui, Gu, Kai, Zhang, Ding, Chen, Shiqing, Wen, Fengcai, Zhong, Hua, Han, Baohui, Zhang, Xueyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499805/ https://www.ncbi.nlm.nih.gov/pubmed/34630387 http://dx.doi.org/10.3389/fimmu.2021.708558

Ejemplares similares

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
por: Xiong, Anning, et al.
Publicado: (2023)

Comut-viz: efficiently creating and browsing comutation plots online
por: Duan, Qiaonan, et al.
Publicado: (2023)

CoMut: visualizing integrated molecular information with comutation plots
por: Crowdis, Jett, et al.
Publicado: (2020)

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
por: Zheng, Liang, et al.
Publicado: (2023)

Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response
por: Hao, Fang, et al.
Publicado: (2022)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
por: West, Howard Jack, et al.
Publicado: (2022)

Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy
por: Qiu, Jiayue, et al.
Publicado: (2022)

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
por: Li, Dan-Ni, et al.
Publicado: (2021)

APOBEC3 proteins can copackage and comutate HIV-1 genomes
por: Desimmie, Belete A., et al.
Publicado: (2016)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
por: Li, Changhui, et al.
Publicado: (2021)

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
por: Coffey, David G., et al.
Publicado: (2022)

Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer
por: Chen, Yu, et al.
Publicado: (2019)

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
por: Wang, Bi-Cheng, et al.
Publicado: (2023)

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma
por: Zhou, Chaozheng, et al.
Publicado: (2021)

Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report
por: Lambert, Nicolas, et al.
Publicado: (2022)

Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials
por: Zhou, Jian-Guo, et al.
Publicado: (2022)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
por: Nie, Wei, et al.
Publicado: (2021)

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer
por: Terai, Hideki, et al.
Publicado: (2015)

BMI1, ATM and DDR
por: Lin, Xiaozeng, et al.
Publicado: (2015)

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527
por: Li, Changhui, et al.
Publicado: (2021)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2021)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
por: Xin, Yujing, et al.
Publicado: (2022)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
por: Zhang, Lei, et al.
Publicado: (2019)

Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report
por: Qin, Zhiquan, et al.
Publicado: (2023)

DDR1 promotes LoVo cell proliferation by regulatingenergy metabolism: Effect of DDR1 on CRC cell metabolic reprogramming
por: Xiong, Bin, et al.
Publicado: (2022)

Discoidin Domain Receptors, DDR1b and DDR2, Promote Tumour Growth within Collagen but DDR1b Suppresses Experimental Lung Metastasis in HT1080 Xenografts
por: Wasinski, Benjamin, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
por: Yang, Zhengyu, et al.
Publicado: (2022)

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs
por: Zhang, Hai, et al.
Publicado: (2020)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
por: Zhang, Bo, et al.
Publicado: (2022)

Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
por: Thompson, Ella R., et al.
Publicado: (2020)

Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
por: Cao, Jin, et al.
Publicado: (2022)

Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings
por: Kushnareva, Ekaterina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tqi1m7vabi4923kja1iddfqdl8